Shearman & Sterling is advising Boston Scientific Corporation on its acquisition of Endo International’s American Medical Systems (AMS) urology portfolio, which includes the men's health and prostate health businesses, in a transaction valued at $1.6 billion, with a potential additional payment of $50 million based on 2016 sales of the business. The company expects to close the transaction in the third quarter of 2015, subject to customary closing conditions.
Based in Minnetonka, Minn., the AMS Men's Health and Prostate Health businesses include approximately 800 employees worldwide, and generated 2014 sales of approximately $400 million and adjusted operating income of approximately $130 million, excluding amortization and certain allocated expenses.
Boston Scientific Corporation is a leading innovator of medical solutions that improve the health of patients around the world. The company’s products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions.
The Shearman & Sterling team included partners Clare O’Brien (New York-Mergers & Acquisitions), Larry Bambino (New York-Tax), John Cannon (New York-Compensation, Governance & ERISA) and Maura O’Sullivan (New York-Finance); counsel Tania Mattei (New York-Mergers & Acquisitions), Richard Alsop (New York-Capital Markets), Jordan Altman (New York-Intellectual Property Transactions), Barbara Edwards (New York-Finance), and Jason Pratt (New York-Environmental); and associates Adam Samarillo, Rob Bucella, Carlos Soto (all New York-Mergers & Acquisitions), Jennifer Stadler (New York-Compensation, Governance & ERISA), Laura Mulry (New York-Environmental), Minsoo Kwon (New York-Capital Markets), Matthew Wochok (Washington, DC-Tax), Katie Butler, Mark Pereira and Emmeline Widjaja (all New York-Corporate).